iRhythm Holdings earnings event shifts investor focus

iRhythm Holdings (IRTC) reported second quarter 2026 revenue of US$224.17 million with a sharply smaller net loss of US$0.381 million, updated its full year revenue guidance, and faces developments in an ongoing securities class action settlement.

The recent earnings beat and higher guidance have not yet reversed the broader share price pressure for iRhythm Holdings, with the share price down 29.71% year to date and total shareholder return down 24.02% over 12 months. This comes even after a 9.43% 1 month share price gain and a strong 5 year total shareholder return of 193.87%, which points to longer term momentum.

If this kind of cardiac monitoring story has your attention, it can be useful to see what else is emerging in healthcare related AI. Take a look at the 44 healthcare AI stocks

iRhythm Holdings now trades at a sizeable discount to both analyst targets and one intrinsic value estimate after its latest rebound. Is this a sensible safety margin given the recent earnings progress and legal overhang, or is the market showing too much caution?

Most Popular Narrative: 31.2% Undervalued

The most followed narrative on iRhythm Holdings sets a fair value of $178.93 per share, compared with the last close at $123.16, which frames a sizable valuation gap for investors to weigh.

Investment in the Zio ecosystem including next-generation patches, enhanced form factors, and AI-powered analytics (such as the Lucem Health partnership) is improving product differentiation, diagnostic yield, and workflow efficiency, likely leading to higher gross margins and operating leverage as software and data become a larger component of the business.

Want to see what sits behind that fair value for iRhythm Holdings? The narrative leans on steady revenue expansion, rising margins, and a future earnings profile that assumes a premium valuation multiple. The exact mix of growth and profitability expectations is critical. The numbers behind that story are where the real debate starts.

Result: Fair Value of $178.93 (UNDERVALUED)

However, iRhythm Holdings still faces meaningful pressure from regulatory scrutiny and potential reimbursement changes, which could weigh on margins and challenge the current undervaluation case.

Another view on iRhythm Holdings valuation

The first narrative for iRhythm Holdings leans on future cash flows and a fair value of $178.93. Yet on a simple P/S basis the picture looks less generous. The stock trades on 4.9x sales, above both the fair ratio of 4.7x and the US Medical Equipment industry at 2.9x, as well as the 4.3x peer average. That richer multiple can be read as a valuation risk if the expected growth and margin improvement take longer than hoped, or it can be seen as the price of access to a business model built around cardiac monitoring and data.

Either way, it is worth asking which story you trust more and what would need to change in the business for those numbers to meet in the middle. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages in the iRhythm Holdings story are clear, so it makes sense to move fast, review the full picture, and decide where you stand based on the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond iRhythm Holdings?

If you want to balance your view on iRhythm Holdings, use the Simply Wall Street Screener to spot fresh opportunities other investors could be overlooking.

• Target potential mispricings by scanning a hand picked group of undervalued companies through the 51 high quality undervalued stocks.
• Strengthen your downside protection by focusing on businesses highlighted in the 88 resilient stocks with low risk scores.
• Get ahead of the crowd by searching for less followed quality stocks using the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.